section name header

Interacting Drugs

OBJECT DRUGS

Kinase Inhibitors:

PRECIPITANT DRUGS

Enzyme Inducers:


Comment:

Although data are limited, these enzyme inducers may decrease the plasma levels of kinase inhibitors. Reduction in the expected antineoplastic activity or resistance may occur. Lapatinib is metabolized into a hepatotoxic metabolite; inducers may increase the risk of hepatotoxicity.


Class 3: Assess Risk & Take Action if Necessary